Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Follow-up Study for Patients Who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES)

NCT02878603 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT02878603
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02878603 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Follow-up Study for Patients Who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES)
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
October 6, 2016
Completion date
October 23, 2020
Enrollment
104 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

acquired thrombotic thrombocytopenic purpura